Video

Dr. Salgia on Crizotinib and Other TKIs in ALK-Positive NSCLC

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

Ravi Salgia, MD, PhD, associate director, Clinical Sciences Research, Arthur & Rosalie Kaplan Chair, Medical Oncology, professor and chair, Department of Medical Oncology & Therapeutics Research, City of Hope, discusses effective agents in the treatment of patients with ALK-positive tumors.

The phase I clinical trial that investigated crizotinib (Xalkori) was initially designed to examine the compound as a MET inhibitor. Investigators later realized that it was also an effective ALK inhibitor, Salgia says. The drug was later approved by the FDA because of its durable progression-free survival in third-line, fourth-line, and fifth-line therapies.

There are other tyrosine-kinase inhibitors for ALK-positive patients, such as ceritinib (Zykadia), brigatinib (Alunbrig), and alectinib (Alecensa). Now, researchers are looking at how to optimally sequence these agents.

Related Videos
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
MATT WAGAR, MD
Dr Kishtagari on Pelabresib Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Manmeet Singh Ahluwalia, MD, MBA, FASCO, chief scientific officer, chief, medical oncology, deputy director, Fernandez Family Endowed Chair in Cancer Research, Baptist Health Miami Cancer Institute
Kelly E. McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA